An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications

References

• Benson L. 2018. Tumor treating fields technology: alternating electric field therapy for the treatment of solid tumors. Semin Oncol Nurs. 34:137–150.
   PubMed Web of Science ®Google Scholar
• Ceresoli G, Aerts J, Madrzak J, Dziadziuszko R, Ramlau R, Cedres S, Hiddinga B, Van Meerbeeck J, Mencoboni M, Planchard D, et al. 2018. MA12.06 STELLAR – final results of a phase 2 trial of TTFields with chemotherapy for first-line treatment of malignant pleural mesothelioma. J Thorac Oncol. 13:S397–S398.
   Web of Science ®Google Scholar
• Chang E, Patel CB, Pohling C, Young C, Song J, Flores TA, Zeng Y, Joubert LM, Arami H, Natarajan A, et al. 2018. Tumor treating fields increases membrane permeability in glioblastoma cells. Cell Death Discov. 4:113.
   PubMed Web of Science ®Google Scholar
• Davies AM, Weinberg U, Palti Y. 2013. Tumor treating fields: a new frontier in cancer therapy. Ann N Y Acad Sci. 1291:86–95.
   PubMed Web of Science ®Google Scholar
• Deans AJ, West SC. 2011. DNA interstrand crosslink repair and cancer. Nat Rev Cancer. 11:467–480.
   PubMed Web of Science ®Google Scholar
• Fu D, Calvo JA, Samson LD. 2012. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer. 12:104–120.
   PubMed Web of Science ®Google Scholar
• Gaillard H, Garcia-Muse T, Aguilera A. 2015. Replication stress and cancer. Nat Rev Cancer. 15:276–289.
   PubMed Web of Science ®Google Scholar
• Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. 2015. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One. 10:e0125269.
   PubMed Web of Science ®Google Scholar
• Giladi M, Lee SY, Hiller R, Chung KY, Khananshvili D. 2015. Structure-dynamic determinants governing a mode of regulatory response and propagation of allosteric signal in splice variants of Na+/Ca2+ exchange (NCX) proteins. Biochem J. 465:489–501.
   PubMed Web of Science ®Google Scholar
• Giladi M, Munster M, Schneiderman RS, Voloshin T, Porat Y, Blat R, Zielinska-Chomej K, Haag P, Bomzon Z, Kirson ED, et al. 2017. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiat Oncol. 12:206.
   PubMed Web of Science ®Google Scholar
• Giladi M, Schneiderman RS, Porat Y, Munster M, Itzhaki A, Mordechovich D, Cahal S, Kirson ED, Weinberg U, Palti Y. 2014. Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. Pancreatology. 14:54–63.
   PubMed Web of Science ®Google Scholar
• Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, et al. 2015. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 5:18046.
   PubMed Web of Science ®Google Scholar
• Giladi M, Weinberg U, Schneiderman RS, Porat Y, Munster M, Voloshin T, Blatt R, Cahal S, Itzhaki A, Onn A, et al. 2014. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo. Semin Oncol. 41 Suppl 6:S35–S41.
   PubMed Web of Science ®Google Scholar
• Glas M, Scheffler B, Lazaridis L, Herrlinger U, Pierscianek D, Sure U, Proescholdt M, Hau P, Hense J, Kleinschnitz C, et al. 2018. PriCoTTF: a phase I/II trial of tumor treating fields prior and concomitant to radiotherapy in newly diagnosed glioblastoma. Neuro-Oncology. 20:vi22–22.
   Google Scholar
• Gonzalez CF, Remcho VT. 2005. Harnessing dielectric forces for separations of cells, fine particles and macromolecules. J Chromatogr A. 1079:59–68.
   PubMed Web of Science ®Google Scholar
• Grosse C, Schwan HP. 1992. Cellular membrane potentials induced by alternating fields. Biophys J. 63:1632–1642.
   PubMed Web of Science ®Google Scholar
• Grosu A, Gkika E, Brunner TB, Thimme R. 2020. Phase II HEPANOVA trial of tumor treating fields concomitant with sorafenib for advanced hepatocellular carcinoma. JCO. 38:TPS603.
   Web of Science ®Google Scholar
• Inui T, Amitani H, Kubo K, Kuchiike D, Uto Y, Nishikata T, Mette M. 2016. Case report: a non-small cell lung cancer patient treated with GcMAF, sonodynamic therapy and tumor treating fields. Anticancer Res. 36:3767–3770.
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. 2005. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 5:689–698.
   PubMed Web of Science ®Google Scholar
• Kanner AA, Wong ET, Villano JL, Ram Z, Investigators EF. 2014. Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A system versus best physician’s choice chemotherapy. Semin Oncol. 41 Suppl:S25–S34.
   Web of Science ®Google Scholar
• Karanam NK, Ding L, Sishc B, Saha D, Story MD. 2018. Abstract 3217: newly identified role of tumor treating fields in DNA damage repair and replication stress pathways. Cancer Res. 78 Supplement:3217–3217.
   Web of Science ®Google Scholar
• Karanam NK, Hao-Ding L, Aroumougame A, Story MD. 2019. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy. Transl Res. 217:33–46.
   PubMed Web of Science ®Google Scholar
• Karanam NK, Srinivasan K, Ding L, Sishc B, Saha D, Story MD. 2017. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines. Cell Death Dis. 8:e2711.
   PubMed Web of Science ®Google Scholar
• Katsir KW, Shahaf GL, Giladi M, Schneiderman RS, Urman N, Gotlieb K, Zeevi E, Porat Y, Munster M, Kinzel A, et al. 2020. Abstract 2411: cancer cell lines meta-analysis according to both short-term and long-term responses to Tumor Treating Fields (TTFields). Cancer Res. 80 Supplement:2411–2411.
   Web of Science ®Google Scholar
• Kessler AF, Frombling GE, Gross F, Hahn M, Dzokou W, Ernestus RI, Lohr M, Hagemann C. 2018. Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition. Cell Death Discov. 5:12.
   Web of Science ®Google Scholar
• Kim EH, Kim YJ, Song HS, Jeong YK, Lee JY, Sung J, Yoo SH, Yoon M. 2016. Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation. Oncotarget. 7:62267–62279.
   PubMedGoogle Scholar
• Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, et al. 2007. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA. 104:10152–10157.
   PubMed Web of Science ®Google Scholar
• Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, Wasserman Y, Ryffel B, Goldsher D, Palti Y. 2009. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 26:633–640.
   PubMed Web of Science ®Google Scholar
• Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. 2004. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 64:3288–3295.
   PubMed Web of Science ®Google Scholar
• Kirson ED, Schneiderman RS, Dbaly V, Tovarys F, Vymazal J, Itzhaki A, Mordechovich D, Gurvich Z, Shmueli E, Goldsher D, et al. 2009. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys. 9:1.
   PubMedGoogle Scholar
• Lu G, Rao M, Zhu P, Liang B, El-Nazer RT, Fonkem E, Bhattacharjee MB. Zhu Jj 2019. Triple-drug therapy with bevacizumab, irinotecan, and temozolomide plus tumor treating fields for recurrent glioblastoma: a retrospective study. Front Neurol. 10:42.
   PubMed Web of Science ®Google Scholar
• Lukas RV, Ratermann KL, Wong ET, Villano JL. 2017. Skin toxicities associated with tumor treating fields: case based review. J Neurooncol. 135:593–599.
   PubMed Web of Science ®Google Scholar
• Maier P, Hartmann L, Wenz F, Herskind C. 2016. Cellular pathways in response to ionizing radiation and their targetability for tumor radiosensitization. Int J Mol Sci. 17:102.
   PubMed Web of Science ®Google Scholar
• Markx GH. 2008. The use of electric fields in tissue engineering: a review. Organogenesis. 4:11–17.
   PubMedGoogle Scholar
• Mehta M, Gondi V, Ahluwalia M, Brown P. 2019. Radiosurgery followed by tumor treating fields for brain metastases (1-10) from Nsclc in the phase 3 Metis Trial. Neuro-Oncology. 21:vi219.
   Web of Science ®Google Scholar
• Morgensztern D, Govindan R. 2010. Best of the month: a roundup of articles published in recent months. J Thorac Oncol. 5:1305–1307.
   PubMed Web of Science ®Google Scholar
• Morgensztern D, Goodgame B, Govindan R. 2010. Vaccines and immunotherapy for non-small cell lung cancer. J Thorac Oncol. 5:S463–S465.
   PubMedGoogle Scholar
• Neuhaus E, Zirjacks L, Ganser K, Klumpp L, Schuler U, Zips D, Eckert F, Huber SM. 2019. Alternating electric fields (TTFields) activate Cav1.2 channels in human glioblastoma cells. Cancers (Basel). 11:110.
   PubMed Web of Science ®Google Scholar
• Pless M, Betticher DC, Droege C, Cathomas R, Weinberg U. 2011. A phase II study of tumor-treating fields (TTF) in combination with pemetrexed for advanced non-small cell lung cancer (NSCLC): updated survival results. JCO. 29:e18030.
   Web of Science ®Google Scholar
• Rivera F, Benavides M, Gallego J, Guillen-Ponce C, Lopez-Martin J, Kung M. 2019. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study. Pancreatology. 19:64–72.
   PubMed Web of Science ®Google Scholar
• Sale JE, Lehmann AR, Woodgate R. 2012. Y-family DNA polymerases and their role in tolerance of cellular DNA damage. Nat Rev Mol Cell Biol. 13:141–152.
   PubMed Web of Science ®Google Scholar
• Salvador E, Kessler A, Hoermann J, Domroese D, Schaeffer C, Burek M, Brami CT, Voloshin T, Giladi M, Ernestus RI, et al. 2020. Tumor treating fields effects on the blood-brain barrier in vitro and in vivo. JCO. 38:2551–2551.
   Web of Science ®Google Scholar
• Schneiderman RS, Shmueli E, Kirson ED, Palti Y. 2010. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters. BMC Cancer. 10:229.
   PubMed Web of Science ®Google Scholar
• Shi W, Kleinberg L, Jeyapalan SA, Goldlust SA, Nagpal S, Reardon DA, Combs SE, Roberge D, Nishigawa R, Glas M. 2020. Phase III TRIDENT trial: radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma. JCO. 38:TPS2580.
   Web of Science ®Google Scholar
• Shteingauz A, Porat Y, Voloshin T, Schneiderman RS, Munster M, Zeevi E, Kaynan N, Gotlib K, Giladi M, Kirson ED, et al. 2018. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields). Cell Death Dis. 9:1074.
   PubMed Web of Science ®Google Scholar
• Silginer M, Weller M, Stupp R, Roth P. 2017. Biological activity of tumor-treating fields in preclinical glioma models. Cell Death Dis. 8:e2753.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, et al. 2017. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 318:2306–2316.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, et al. 2015. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 314:2535–2543.
   PubMed Web of Science ®Google Scholar
• Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbaly V, et al. 2012. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 48:2192–2202.
   PubMed Web of Science ®Google Scholar
• Turner N, Tutt A, Ashworth A. 2004. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 4:814–819.
   PubMed Web of Science ®Google Scholar
• Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C. 2018. Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: results of the INNOVATE pilot study. Gynecol Oncol. 150:471–477.
   PubMed Web of Science ®Google Scholar
• Voloshin T, Davidi S, Porat Y, Shteingauz A, Munster M, Kaynan N, Giladi M, Kirson E, Weinberg U, Plati Y. 2018. Immu-52. Tumor Treating Fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Neuro-Oncology. 20:vi133.
   Web of Science ®Google Scholar
• Voloshin T, Munster M, Blatt R, Shteingauz A, Roberts PC, Schmelz EM, Giladi M, Schneiderman RS, Zeevi E, Porat Y, et al. 2016. Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo. Int J Cancer. 139:2850–2858.
   PubMed Web of Science ®Google Scholar
• Vymazal J, Wong ET. 2014. Response patterns of recurrent glioblastomas treated with tumor-treating fields. Semin Oncol. 41 Suppl:S14–S24.
   Web of Science ®Google Scholar
• Wang D, Lippard SJ. 2005. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320.
   PubMed Web of Science ®Google Scholar
• Wang Y, Pandey M, Ballo MT. 2019. Integration of Tumor-Treating Fields into the multidisciplinary management of patients with solid malignancies. Oncologist. 24:e1426–e1436.
   PubMed Web of Science ®Google Scholar
• Weinberg U, Farber O, Giladi M, Bomzon Z, Kirson E. 2019. Tumor Treating Fields (150 kHz) concurrent with standard of care treatment for stage 4 non-small cell lung cancer (NSCLC) following platinum failure: the Phase III LUNAR study. Cancer Res. 79:CT173.
   Web of Science ®Google Scholar
• Wenger C, Giladi M, Bomzon Z, Salvador R, Basser PJ, Miranda PC. 2015. Modeling Tumor Treating Fields (TTFields) application in single cells during metaphase and telophase. Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society; Aug 25–29; Milan, Italy. p. 6892–6895.
   Google Scholar
• Wong ET, Lok E, Gautam S, Swanson KD. 2015. Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. Br J Cancer. 113:1642.
   PubMed Web of Science ®Google Scholar
• Wong ET, Lok E, Swanson KD, Gautam S, Engelhard HH, Lieberman F, Taillibert S, Ram Z, Villano JL. 2014. Response assessment of NovoTTF-100A versus best physician’s choice chemotherapy in recurrent glioblastoma. Cancer Med. 3:592–602.
   PubMed Web of Science ®Google Scholar
• Zhang J, Dai Q, Park D, Deng X. 2016. Targeting DNA replication stress for cancer therapy. Genes (Basel). 7:51.
   Web of Science ®Google Scholar